Literature DB >> 9869347

Treatment of deep and shallow intrabony defects. A multicenter randomized controlled clinical trial.

P Cortellini1, G Carnevale, M Sanz, M S Tonetti.   

Abstract

This prospective multicenter intra-individual randomized controlled clinical trial was designed to compare the efficacy of guided tissue regeneration (GTR) with bioresorbable barrier membranes versus access flap surgery, in intrabony defects. 2 similar defects were selected in each of 23 patients and randomly assigned to 1 of the 2 treatments. Surgery consisted of an identical procedure except for the omission of the barrier membrane in the flap control sites. At 1-year, probing pocket depth reductions were 4.3+/-2.3 mm in GTR treated sites and 3.0+/-1.5 mm in the flap control sites (p=0.02, paired t-test). Clinical attachment level (CAL) gains were 3.0+/-1.7 mm in the GTR sites and 1.6+/-1.8 mm in the control sites (p=0.009, paired t-test). A subset analysis, performed according to the initial depth of the intrabony component of the defects (INFRA), indicated that in shallow defects (INFRA < or =3 mm) treated with the access flap alone, CAL gains were 1+/-1.5 mm, while in deep ones (INFRA > or =4 mm) they were consistently greater (1.9+/-1.9 mm). The % CAL gains, calculated as the % of the baseline intrabony component depth, however, were almost identical in the 2 subpopulations (45.8+/-64.7% in shallow and 43.8+/-37.6% in deep defects). Similarly, in the GTR sites, linear CAL gains were greater in deep (3.7+/-1.7 mm) than in shallow defects (2.2+/-1.3 mm), but no differences were observed in terms of % CAL gains (76.7+/-27.7% and 75.8+/-45%, respectively). The frequency distribution of CAL changes expressed as %s of the baseline INFRA indicates that most of the sites treated with GTR (73% in shallow and 92% in deep defects) gained 50% or more CAL. Furthermore, many defects (64% of shallow and 33% of deep defects) reached 100% of CAL gain. The present study demonstrated that: (i) GTR with bioresorbable barrier membranes resulted in a significant added benefit in comparison with access flap alone; (ii) the linear amounts of CAL gains were greater in deep than in shallow defects; (iii) CAL gains expressed as %s of the baseline depths of the intrabony component, were similar in shallow and deep defects; (iii) the regenerative procedure tested in the present study resulted in CAL gains equal to the depth of the intrabony component of the defect in some, but not in most of the instances.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9869347     DOI: 10.1111/j.1600-051x.1998.tb02402.x

Source DB:  PubMed          Journal:  J Clin Periodontol        ISSN: 0303-6979            Impact factor:   8.728


  21 in total

1.  Demineralized freeze-dried bone allograft and platelet-rich plasma vs platelet-rich plasma alone in infrabony defects: a clinical and radiographic evaluation.

Authors:  Tunç Ilgenli; Nesrin Dündar; Betül Ilhan Kal
Journal:  Clin Oral Investig       Date:  2006-12-09       Impact factor: 3.573

2.  Levels of gingival tissue platelet activating factor after conventional and regenerative periodontal surgery.

Authors:  Gonca Cayir Keles; Burcu Ozkan Cetinkaya; Bulent Ayas; Ibrahim Isildak; Emine Diraman; Hulya Koprulu; Gokhan Acikgoz
Journal:  Clin Oral Investig       Date:  2007-05-24       Impact factor: 3.573

3.  Healing of intrabony defects following treatment with an oily calcium hydroxide suspension (Osteoinductal). A controlled clinical study.

Authors:  Stefan-Ioan Stratul; Frank Schwarz; Jürgen Becker; Britta Willershausen; Anton Sculean
Journal:  Clin Oral Investig       Date:  2005-12-20       Impact factor: 3.573

Review 4.  WITHDRAWN: Guided tissue regeneration for periodontal infra-bony defects.

Authors:  Ian Needleman; Helen V Worthington; Elaine Giedrys-Leeper; Richard Tucker
Journal:  Cochrane Database Syst Rev       Date:  2019-05-29

5.  Treatment of intrabony periodontal defects in controlled diabetic patients with an enamel matrix derivative: a split-mouth randomized clinical trial.

Authors:  Renata Cimões; Leógenes M Santiago; Arnaldo de França Caldas Júnior; Bruna de Carvalho Farias Vajgel; Jeniffer Perussolo; Nikolaos Donos
Journal:  Clin Oral Investig       Date:  2021-10-13       Impact factor: 3.606

6.  Effect of autogenous cortical bone grafting in conjunction with guided tissue regeneration in the treatment of intraosseous periodontal defects.

Authors:  Gonca Cayir Keles; Mahmut Sumer; Burcu Ozkan Cetinkaya; Ferda Tutkun; S Burcak Simsek
Journal:  Eur J Dent       Date:  2010-10

7.  Treatment of intrabony defects with guided tissue regeneration in aggressive periodontitis: clinical outcomes at 6 and 12 months.

Authors:  Thanasak Rakmanee; Gareth S Griffiths; Gita Auplish; Ulpee Darbar; Aviva Petrie; Irwin Olsen; Nikolaos Donos
Journal:  Clin Oral Investig       Date:  2015-09-28       Impact factor: 3.573

8.  Clinical evaluation of anorganic bovine-derived hydroxyapatite matrix/cell-binding peptide (P-15) in the treatment of human infrabony defects.

Authors:  Adrian Kasaj; Bernd Röhrig; Christoph Reichert; Brita Willershausen
Journal:  Clin Oral Investig       Date:  2008-03-05       Impact factor: 3.573

9.  A primer on network meta-analysis for dental research.

Authors:  Yu-Kang Tu; Clovis Mariano Faggion
Journal:  ISRN Dent       Date:  2012-06-21

10.  Autogenous cortical bone and bioactive glass grafting for treatment of intraosseous periodontal defects.

Authors:  Mahmut Sumer; Gonca Cayir Keles; Burcu Ozkan Cetinkaya; Umut Balli; Ferda Pamuk; Sina Uckan
Journal:  Eur J Dent       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.